LOG IN
SIGN UP
MARKET
OCUL
OCUL
Ocular Therapeut
NASDAQ
Real-time Quotes | Nasdaq Last Sale
3.010
-0.050
-1.63%
After Hours: 3.010 0 0.00% 16:00 05/26 EDT
OPEN
3.060
PREV CLOSE
3.060
HIGH
3.070
LOW
2.950
VOLUME
510.39K
TURNOVER
0
52 WEEK HIGH
15.32
52 WEEK LOW
2.950
MARKET CAP
231.05M
P/E (TTM)
-10.2486
1D
5D
1M
3M
1Y
5Y
Scholar Rock, Phathom top healthcare gainers; PolarityTE, Tonix lead losers' pack
Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) -18%. Ac...
Seekingalpha · 05/17 14:03
--Berenberg Bank Cuts Price Target on Ocular Therapeutix to $21 From $23, Maintains Buy Rating
MT Newswires · 05/11 07:50
Expert Ratings for Ocular Therapeutix
Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade...
Benzinga · 05/10 17:03
--HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $14, Reiterates Buy Rating
MT Newswires · 05/10 09:26
Piper Sandler Adjusts Price Target on Ocular Therapeutix to $16 From $20, Reiterates Overweight Rating
MT Newswires · 05/10 07:23
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 21:45
BRIEF-Ocular Posts Quarterly Net Loss Per Share, Diluted $0.22
reuters.com · 05/09 21:13
Ocular Therapeutix Q1 EPS $(0.22) Beats $(0.26) Estimate, Sales $13.19M Miss $14.20M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.24) per share from
Benzinga · 05/09 20:12
No Data
Learn about the latest financial forecast of OCUL. Analyze the recent business situations of Ocular Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 7 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
28.57%Strong Buy
57.14%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OCUL stock price target is 17.71 with a high estimate of 29.00 and a low estimate of 10.00.
Current 3.010
EPS
Actual
Estimate
-0.21-0.15-0.09-0.02
Institutional Holdings
Institutions: 171
Institutional Holdings: 42.12M
% Owned: 54.87%
Shares Outstanding: 76.76M
TypeInstitutionsShares
Increased
51
4.39M
New
27
935.63K
Decreased
42
3.61M
Sold Out
27
4.68M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.31%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Charles Warden
President/Chief Executive Officer/Director
Antony Mattessich
Chief Financial Officer
Donald Notman
Corporate Executive
Michael Goldstein
General Counsel
Philip Strassburger
Director
Merilee Raines
Independent Director
Jeffrey Heier
Independent Director
Seung Suh Hong
Independent Director
Richard Lindstrom
Independent Director
Bruce Peacock
Independent Director
Leslie Williams
No Data
No Data
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which is focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.
Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.